Fiche publication
Date publication
juin 2026
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François
,
Dr NARDIN Charlée
Tous les auteurs :
Erard T, Quéreux G, Amini-Adle M, Montaudié H, Charles J, Puyraveau M, Jeudy G, Bernard P, Grange F, Legoupil D, Zehou O, Celerier P, Lesage C, Khammari A, Aubin F, Nardin C
Lien Pubmed
Résumé
The approval of adjuvant treatment with anti-PD-1 antibodies (anti-PD-1) and BRAF and MEK inhibitors (BRAFi/MEKi) for resected stage III/IV melanoma was based on randomized controlled trials demonstrating a benefit in recurrence-free survival (RFS). However, none showed a significant impact on overall survival (OS). We aimed to evaluate the OS impact of adjuvant therapies in real-world settings.
Mots clés
Adjuvant treatment, Anti-PD-1, BRAF V600, BRAFi/MEKi, Immunotherapy, Melanoma, Overall survival, Recurrence-free survival
Référence
Eur J Cancer. 2026 06 25;244:116878
